Salmonella typhimurium suppresses tumor growth via the pro-inflammatory cytokine interleukin-1β

Theranostics

Volumn 5, Issue 12, 2015, Pages 1328-1342

  Kim, Jung Eun ^b,c   Phan, Thuy Xuan ^a   Nguyen, Vu Hong ^a   Dinh Vu, Hong Van ^a   Zheng, Jin Hai ^a   Yun, Misun ^a   Park, Sung Gyoo ^b   Hong, Yeongjin ^a   Choy, Hyon E ^a   Szardenings, Michael ^d   Hwang, Won ^b,c   Park, Jin A ^c   Park, SunHee ^c   Im, Sin Hyeog ^c,e   Min, Jung Joon ^a  

^a Chonnam National University Medical School   (South Korea)

^b Gwangju Institute of Science and Technology (GIST)   (South Korea)

^c Institute for Basic Science   (South Korea)

^d FRAUNHOFER INSTITUTE FOR CELL THERAPY AND IMMUNOLOGY   (Germany)

^e Pohang University of Science and Technology (POSTECH)   (South Korea)

Author keywords

Bacteria mediated cancer therapy; Dendritic cells; E. coli; IL 1 ; Salmonella typhimurium; TNF

Indexed keywords

ANTINEOPLASTIC AGENT; INTERLEUKIN 1BETA; MG 1655; MOLECULAR THERAPY AGENT; ONCOLYTIC BACTERIA; RECOMBINANT INTERLEUKIN 1BETA; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; CANCER INHIBITION; CANCER REGRESSION; CANCER STAGING; CELL POPULATION; COLON ADENOCARCINOMA; CONTROLLED STUDY; DENDRITIC CELL; DRUG CYTOTOXICITY; DRUG POTENTIATION; ESCHERICHIA COLI; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; MACROPHAGE; MALE; MOUSE; NONHUMAN; SALMONELLA ENTERICA SEROVAR TYPHIMURIUM; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; BIOLOGICAL THERAPY; DISEASE MODEL; IMMUNOLOGY; NEOPLASMS; PATHOLOGY; PROCEDURES;

ANIMALS; BIOLOGICAL THERAPY; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI; INTERLEUKIN-1BETA; MACROPHAGES; MALE; MICE, INBRED BALB C; NEOPLASMS; SALMONELLA TYPHIMURIUM; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84948132555     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.11432     Document Type: Article

References (67)

1. Coley WB. Treatment of inoperable malignant tumors with the toxines of erysipelas and the bacillus prodigiosus. Am J Med Sci. 1894; 108: 50-66.
2. Forbes NS. Engineering the perfect (bacterial) cancer therapy. Nat Rev Cancer. 2010; 10: 785-94.
3. Barbé S, Van Mellaert L, Anné J. The use of clostridial spores for cancer treatment. J Appl Microbiol. 2006; 101: 571-8.
4. Lemmon M, Van Zijl P, Fox M, Mauchline M, Giaccia A, Minton N, et al. Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment. Gene Ther. 1997; 4: 791-6.
5. Liu S, Minton N, Giaccia A, Brown J. Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. Gene Ther. 2002; 9: 291-6.
6. Nuyts S, Van Mellaert L, Theys J, Landuyt W, Lambin P, Anné J. Clostridium spores for tumor-specific drug delivery. Anticancer Drugs. 2002; 13: 115-25.
7. Avogadri F, Martinoli C, Petrovska L, Chiodoni C, Transidico P, Bronte V, et al. Cancer immunotherapy based on killing of Salmonella-infected tumor cells. Cancer Res. 2005; 65: 3920-7.
8. Loeffler M, Le'Negrate G, Krajewska M, Reed JC. Attenuated Salmonella engineered to produce human cytokine LIGHT inhibit tumor growth. Proc Natl Acad Sci U S A. 2007; 104: 12879-83.
9. Nguyen VH, Kim H-S, Ha J-M, Hong Y, Choy HE, Min J-J. Genetically engineered Salmonella typhimurium as an imageable therapeutic probe for cancer. Cancer Res. 2010; 70: 18-23.
10. Pawelek JM, Low KB, Bermudes D. Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res. 1997; 57: 4537-44.
11. Zhao M, Yang M, Li X-M, Jiang P, Baranov E, Li S, et al. Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc Natl Acad Sci U S A. 2005; 102: 755-60.
12. Yazawa K, Fujimori M, Nakamura T, Sasaki T, Amano J, Kano Y, et al. Bifidobacterium longum as a delivery system for gene therapy of chemically induced rat mammary tumors. Breast Cancer Res Treat. 2001; 66: 165-70.
13. Min J-J, Kim H-J, Park JH, Moon S, Jeong JH, Hong Y-J, et al. Noninvasive real-time imaging of tumors and metastases using tumor-targeting light-emitting Escherichia coli. Mol Imaging Biol. 2008; 10: 54-61.
14. Jiang S-N, Phan TX, Nam T-K, Nguyen VH, Kim H-S, Bom H-S, et al. Inhibition of tumor growth and metastasis by a combination of Escherichia coli-mediated cytolytic therapy and radiotherapy. Mol Ther. 2010; 18: 635-42.
15. Yoshimura K, Jain A, Allen HE, Laird LS, Chia CY, Ravi S, et al. Selective targeting of antitumor immune responses with engineered live-attenuated Listeria monocytogenes. Cancer Res. 2006; 66: 1096-104.
16. Jeong J-H, Kim K, Lim D, Jeong K, Hong Y, Nguyen VH, et al. Anti-tumoral effect of the mitochondrial target domain of Noxa delivered by an engineered Salmonella typhimurium. PloS One. 2014; 9: e80050.
17. Jiang S-N, Park S-H, Lee HJ, Zheng JH, Kim H-S, Bom H-S, et al. Engineering of bacteria for the visualization of targeted delivery of a cytolytic anticancer agent. Mol Ther. 2013.
18. Kim K, Jeong JH, Lim D, Hong Y, Yun M, Min J-J, et al. A novel balanced-lethal host-vector system based on glmS. PloS One. 2013; 8: e60511.
19. Min J-J, Nguyen VH, Kim H-J, Hong Y, Choy HE. Quantitative bioluminescence imaging of tumor-targeting bacteria in living animals. Nat Protoc. 2008; 3: 629-36.
20. Park SJ, Park S-H, Cho S, Kim D-M, Lee Y, Ko SY, et al. New paradigm for tumor theranostic methodology using bacteria-based microrobot. Sci Rep. 2013; 3.
21. Degré M. Cytokines and bacterial infections. Biotherapy. 1996; 8: 219-28.
22. Reisser D, Pance A, Jeannin JF. Mechanisms of the antitumoral effect of lipid A. Bioessays. 2002; 24: 284-9.
23. Weibel S, Stritzker J, Eck M, Goebel W, Szalay AA. Colonization of experimental murine breast tumours by Escherichia coli K-12 significantly alters the tumour microenvironment. Cell Microbiol. 2008; 10: 1235-48.
24. Leschner S, Westphal K, Dietrich N, Viegas N, Jablonska J, Lyszkiewicz M, et al. Tumor invasion of Salmonella enterica serovar Typhimurium is accompanied by strong hemorrhage promoted by TNF-alpha. PLoS One. 2009; 4: e6692.
25. Theys J, Nuyts S, Landuyt W, Van Mellaert L, Dillen C, Böhringer M, et al. Stable Escherichia coli-Clostridium acetobutylicum shuttle vector for secretion of murine tumor necrosis factor alpha. Appl Environ Microbiol. 1999; 65: 4295-300.
26. Hong E-H, Chang S-Y, Lee B-R, Pyun AR, Kim J-W, Kweon M-N, et al. Intratumoral injection of attenuated Salmonella vaccine can induce tumor microenvironmental shift from immune suppressive to immunogenic. Vaccine. 2013; 31: 1377-84.
27. Bosslet K, Ruffmann R, Altevogt P, Schirrmacher V. A rapid method for the isolation of metastasizing tumour cells from internal organs with the help of isopycnic density-gradient centrifugation in Percoll. Br J Cancer. 1981; 44: 356-62.
28. Liu F, Zhang L, Hoffman RM, Zhao M. Vessel destruction by tumor-targeting Salmonella typhimurium A1-R is enhanced by high tumor vascularity. Cell Cycle. 2010; 9: 4518-24.
29. Coburn B, Grassl GA, Finlay B. Salmonella, the host and disease: a brief review. Immunol Cell Biol. 2006; 85: 112-8.
30. Vendrell A, Gravisaco MJ, Pasetti MF, Croci M, Colombo L, Rodríguez C, et al. A novel Salmonella Typhi-based immunotherapy promotes tumor killing via an antitumor Th1-type cellular immune response and neutrophil activation in a mouse model of breast cancer. Vaccine. 2011; 29: 728-36.
31. Wick MJ. Living in the danger zone: innate immunity to Salmonella. Curr Opin Microbiol. 2004; 7: 51-7.
32. Hope C, Ollar SJ, Heninger E, Hebron E, Jensen JL, Kim J, et al. TPL2 kinase regulates the inflammatory milieu of the myeloma niche. Blood. 2014; 123: 3305-15.
33. Youn J-I, Kumar V, Collazo M, Nefedova Y, Condamine T, Cheng P, et al. Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. Nat Immunol. 2013; 14: 211-20.
34. Wolf D, Wolf AM, Rumpold H, Fiegl H, Zeimet AG, Muller-Holzner E, et al. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res. 2005; 11: 8326-31.
35. Martin-Orozco N, Li Y, Wang Y, Liu S, Hwu P, Liu Y-J, et al. Melanoma cells express ICOS ligand to promote the activation and expansion of T-regulatory cells. Cancer Res. 2010; 70: 9581-90.
36. Anz D, Mueller W, Golic M, Kunz WG, Rapp M, Koelzer VH, et al. CD103 is a hallmark of tumor-infiltrating regulatory T cells. Int J Cancer. 2011; 129: 2417-26.
37. Yu HB, Finlay BB. The caspase-1 inflammasome: a pilot of innate immune responses. Cell Host Microbe. 2008; 4: 198-208.
38. Männel D, Moore R, Mergenhagen S. Macrophages as a source of tumoricidal activity (tumor-necrotizing factor). Infect Immun. 1980; 30: 523-30.
39. Ganai S, Arenas R, Forbes N. Tumour-targeted delivery of TRAIL using Salmonella typhimurium enhances breast cancer survival in mice. Br J Cancer. 2009; 101: 1683-91.
40. Nuyts S, Van Mellaert L, Theys J, Landuyt W, Bosmans E, Anné J, et al. Radio-responsive recA promoter significantly increases TNFalpha production in recombinant clostridia after 2 Gy irradiation. Gene Ther. 2001; 8: 1197-201.
41. Kaimala S, Mohamed Y, Nader N, Issac J, Elkord E, Chouaib S, et al. Salmonella-mediated tumor regression involves targeting of tumor myeloid suppressor cells causing a shift to M1-like phenotype and reduction in suppressive capacity. Cancer Immunol Immunother. 2014; 63: 587-99.
42. Blankenstein T, Qin Z, Uberla K, Müller W, Rosen H, Volk H-D, et al. Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer. J Exp Med. 1991; 173: 1047-52.
43. Leong K, Karsan A. Signaling pathways mediated by tumor necrosis factor alpha. Histol Histopathol. 2000; 15: 1303-25.
44. Sanlioglu AD, Aydin C, Bozcuk H, Terzioglu E, Sanlioglu S. Fundamental principals of tumor necrosis factor-alpha gene therapy approach and implications for patients with lung carcinoma. Lung Cancer. 2004; 44: 199-211.
45. Asher A, Mulé JJ, Reichert CM, Shiloni E, Rosenberg SA. Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol. 1987; 138: 963-74.
46. Verhoef C, de Wilt JH, Grünhagen DJ, van Geel AN, ten Hagen TL, Eggermont AM. Isolated limb perfusion with melphalan and TNF-alpha in the treatment of extremity sarcoma. Curr Treat Options Oncol. 2007; 8: 417-27.
47. Chen LC, Wang LJ, Tsang NM, Ojcius DM, Chen CC, OuYang CN, et al. Tumour inflammasome-derived IL-1ß recruits neutrophils and improves local recurrence-free survival in EBV-induced nasopharyngeal carcinoma. EMBO Mol Med. 2012; 4: 1276-93.
48. Netea MG, Nold-Petry CA, Nold MF, Joosten LAB, Opitz B, van der Meer JHM, et al. Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. Blood. 2009; 113: 2324-35.
49. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med. 2009; 15: 1170-8.
50. Hazuda DJ, Strickler J, Kueppers F, Simon PL, Young PR. Processing of precursor interleukin 1 beta and inflammatory disease. J Biol Chem. 1990; 265: 6318-22.
51. Guma M, Ronacher L, Liu-Bryan R, Takai S, Karin M, Corr M. Caspase 1-independent activation of interleukin-1beta in neutrophil-predominant inflammation. Arthritis Rheum. 2009; 60: 3642-50.
52. van de Veerdonk FL, Netea MG, Dinarello CA, Joosten LA. Inflammasome activation and IL-1ß and IL-18 processing during infection. Trends Immunol. 2011; 32: 110-6.
53. Franchi L, Amer A, Body-Malapel M, Kanneganti T-D, Ozoren N, Jagirdar R, et al. Cytosolic flagellin requires Ipaf for activation of caspase-1 and interleukin 1beta in salmonella-infected macrophages. Nat Immunol. 2006; 7: 576-82.
54. Krelin Y, Voronov E, Dotan S, Elkabets M, Reich E, Fogel M, et al. Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. Cancer Res. 2007; 67: 1062-71.
55. Talmadge JE, Donkor M, Scholar E. Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metastasis Rev. 2007; 26: 373-400.
56. Voronov E, Shouval DS, Krelin Y, Cagnano E, Benharroch D, Iwakura Y, et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci U S A. 2003; 100: 2645-50.
57. Yoo SY, Lee SY, Yoo NC. Cytokine expression and cancer detection. Med Sci Monit. 2009; 15: RA49-RA56.
58. Carmi Y, Rinott G, Dotan S, Elkabets M, Rider P, Voronov E, et al. Microenvironment-derived IL-1 and IL-17 interact in the control of lung metastasis. J Immunol. 2011; 186: 3462-71.
59. Carrier MJ, Chatfield SN, Dougan G, Nowicka U, O'Callaghan D, Beesley JE, et al. Expression of human IL-1 beta in Salmonella typhimurium. A model system for the delivery of recombinant therapeutic proteins in vivo. J Immunol. 1992; 148: 1176-81.
60. Friedlander RM, Gagliardini V, Rotello RJ, Yuan J. Functional role of interleukin 1 beta (IL-1 beta) in IL-1 beta-converting enzyme-mediated apoptosis. J Exp Med. 1996; 184: 717-24.
61. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008; 8: 59-73.
62. Aymeric L, Apetoh L, Ghiringhelli F, Tesniere A, Martins I, Kroemer G, et al. Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res. 2010; 70: 855-8.
63. Song M, Kim H-J, Kim EY, Shin M, Lee HC, Hong Y, et al. ppGpp-dependent stationary phase induction of genes on Salmonella pathogenicity island 1. J Biol Chem. 2004; 279: 34183-90.
64. Zhao M, Yang M, Ma H, Li X, Tan X, Li S, et al. Targeted therapy with a Salmonella typhimurium leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice. Cancer Res. 2006; 66: 7647-52.
65. Zhao M, Geller J, Ma H, Yang M, Penman S, Hoffman RM. Monotherapy with a tumor-targeting mutant of Salmonella typhimurium cures orthotopic metastatic mouse models of human prostate cancer. Proc Natl Acad Sci U S A. 2007; 104: 10170-4.
66. Yam C, Zhao M, Hayashi K, Ma H, Kishimoto H, McElroy M, et al. Monotherapy with a tumor-targeting mutant of S. typhimurium inhibits liver metastasis in a mouse model of pancreatic cancer. J Surg Res. 2010; 164: 248-55.
67. Yano S, Zhang Y, Zhao M, Hiroshima Y, Miwa S, Uehara F, et al. Tumor-targeting Salmonella typhimurium A1-R decoys quiescent cancer cells to cycle as visualized by FUCCI imaging and become sensitive to chemotherapy. Cell Cycle. 2014; 13: 3958-63.